Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » The Scan » Not Much of a Choice, Anyway

Not Much of a Choice, Anyway

Feb 24, 2009

With credit tight and investors skittish, a hostile takeover of Genentech by Roche might not be that big of a deal, says an article in the San Jose Mercury News. And in any case, it's possible Genentech employees won't have many options these days when it comes to finding other jobs.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Plans Out

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

CovidNudge Numbers

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

Science Papers Propose Group to Discuss Genome-Editing Tools, Markers of Diabetes Drug Response, More

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

Not Counting These

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Oct
06
Featured Webinar

Understanding Human Pulmonary Fibrosis using Single-Cell Technologies

Sponsored by
10x Genomics

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease characterized by irreversible scarring of the distal lung, leading to respiratory failure. 

What's Popular?

In Drug Discovery & Development

  1. Hexagon Bio Raises $47M in Series A Round

  2. Genetron Health, DMed Enter Pharma Services Partnership

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.